Canaccord analyst Richard Close lowered the firm’s price target on Clover Health to $3.00 from $4.00 and keeps a Buy rating on the shares. The analyst said Clover has dialed-back its MA expansion and reduced its participation in ACO REACH for 2023, which should help the company drive meaningful improvement to MCR trends. We remain cautiously optimistic as Clover proves its tech-enabled population health management offering.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLOV:
- Clover Health Gains on Robust Q4
- Unusually active option classes on open February 28th
- Clover Health reports Q4 revenue $898.8M, consensus $785.38M
- Clover Health Reports Fourth Quarter and Full Year 2022 Financial Results
- Clover Health to Present at Citi’s 2023 Healthcare Conference on March 1, 2023
